Brain Cancer
Ishii D, Natsume A, Wakabayashi T, Hatano H, Asano Y, Takeuchi H, Shimato S, Ito M, Fujii M, Yoshida J.
Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
Neurol Med Chir (Tokyo). 2007;47(8):341-9.
Weaver KD, Grossman SA, Herman JG.
Methylated tumor-specific DNA as a plasma biomarker in patients with glioma.
Cancer Invest. 2006;24(1):35-40.
Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK.
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Pediatr Blood Cancer. 2007;48(4):403-7.
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R.
MGMT gene silencing and benefit from temozolomide in glioblastoma.
N Engl J Med. 2005;352(10):997-1003.
Additional Publications
Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L, Garcia-Lopez JL, Piquer J, Safont MJ, Balana C, Sanchez-Cespedes M, Garcia-Villanueva M, Arribas L, Esteller M.
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
Clin Cancer Research 2004; 10(15): 4933-8
Esteller M, Garcia-Foncillas J, Andion E, Goodman, S, Hidalgo O, Vanaclocha V, Baylin SB, Herman, JG.
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
N Engl J Med. 2000;343(19):1350-4.
Watanabe T, Katayama Y, Komine C, Yoshino A, Ogino A, Ohta T, Fukushima T.
O6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course.
Int J Cancer. 2005;113(4):581-7.
Abe M, Ohira M, Kaneda A, Yagi Y, Yamamoto S, Kitano Y, Takato T, Nakagawara A, Ushijima T.
CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas.
Cancer Res. 2005;65(3):828-34.
Mollemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G.
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.
Int J Cancer. 2005;113(3):379-85.
Alaminos M, Davalos V, Cheung NK, Gerald WL, Esteller M.
Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma.
J Natl Cancer Inst. 2004;96(16):1208-19.
Hegi ME, Diserens A-C, Godard S, Dietrich P-Y, Regli L, Osterman S, Otten P, Van Melle de Tribolet N, Stupp R.
Clinical trial substantiates the predictive value of O6-MGMT promoter methylation in glioblastoma patients treated with Temozolomide.
Clin. Cancer Res. 2004;10:1871-4
Kamiryo T, Tada K, Shiraishi S, Shinojima N, Kochi M, Ushio Y.
Correlation between promoter hypermethylation of the MGMT gene and prognosis in patients with high grade astrocytic tumors treated with surgery, radiotherapy, & ACNU-based chemotherapy.
Neurosurgery 2004;54(2):349-56.